The objective of this study was to retrospectively evaluate the clinical and immunological effects of anti-B cell treatment in patients with systemic lupus erythematosus (SLE) and mixed connective-tissue disease (MCTD) with autoimmune thrombocytopenia (AITP) refractory to conventional immunosuppressive treatment.
Methods
Rituximab (RTX) was added to the ongoing treatment of 16 patients (median age 36 years, range 17–84, all female) with treatment-resistant AITP. Thirteen patients had SLE and three had MCTD. RTX was given intravenously on four occasions during four consecutive weeks at a dose of 375 mg/m2. Clinical and laboratory disease activity variables recorded at every follow-up visit were analyzed.
Results
The median disease duration before RTX treatment was nine years (range 0.2–27) and the median post-treatment follow-up time was 28 months (range 3 to 92). Ten patients (63%) were treated repeatedly with RTX during the follow-up period. Complete depletion of B cells was achieved in 94% of cases one month after RTX treatment. A significant increase (p = 0.0001) of platelet counts was seen already after one month (median 58 × 109/ml vs 110 × 109/ml) whereas within three months platelet counts normalized in 10 patients (median 223 × 109/ml). Three patients did not respond to RTX treatment (median platelet count 69 × 109/ml). High titers of anti-platelet antibodies were detected in seven patients before RTX treatment, and the autoantibody titers decreased significantly (p < 0.03) after RTX treatment in six of these patients who also achieved complete remission. A review of the literature revealed 24 articles including 18 case reports, one retrospective cohort study and five prospective studies documenting the outcomes of 65 RTX-treated patients with SLE- or MCTD-related thrombocytopenia with an overall treatment response rate of 80%. In conclusion, these findings indicate that RTX is an additional potent therapeutic treatment option for SLE patients with AITP refractory to conventional immunosuppressive treatment whereas best response may be expected in patients with high titers of anti-platelet antibodies at baseline.
DornerTGieseckeCLipskyPE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther2011; 13: 243–243.
2.
MartinFChanAC. B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol2006; 24: 467–496.
3.
HoffmanRWMaldonadoME. Immune pathogenesis of mixed connective tissue disease: A short analytical review. Clin Immunol2008; 128: 8–17.
4.
KumarSBenselerSMKirby-AllenMSilvermanED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics2009; 123: e159–e163.
5.
SultanSMBegumSIsenbergDA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford)2003; 42: 230–234.
6.
NossentJCSwaakAJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med1991; 80: 605–612.
7.
MokCCLeeKWHoCTLauCSWongRW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford)2000; 39: 399–406.
8.
ZiakasPDGiannouliSZintzarasETzioufasAGVoulgarelisM. Lupus thrombocytopenia: Clinical implications and prognostic significance. Ann Rheum Dis2005; 64: 1366–1369.
9.
HepburnALNaratSMasonJC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford)2010; 49: 2243–2254.
SmithHRSteinbergAD. Autoimmunity—a perspective. Annu Rev Immunol1983; 1: 175–210.
12.
ArnalCPietteJCLéoneJ. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol2002; 29: 75–83.
13.
CooperNStasiRCunningham-RundlesS. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol2004; 125: 232–239.
14.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
15.
KasukawaRTojoTMiyawakiSPreliminary diagnostic criteria for classification of mixed connective tissue disease. In: KasukawaRSharpGC (eds). Mixed connective tissue disease and antinuclear antibodies, Amsterdam: Elsevier, 1987, pp. 41–47.
16.
Alarcón-SegoviaDCardielMH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol1989; 16: 328–334.
17.
LindholmCBörjesson-AspKZendjanchiKSundqvistACTarkowskiABokarewaM. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol2008; 35: 826–833.
18.
ChenHZhengWSuJ. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study. Rheumatology (Oxford)2011; 50: 1640–1644.
19.
Mestanza-PeraltaMAriza-ArizaRCardielMHAlcocer-VarelaJ. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol1997; 24: 867–870.
DornerT. Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells. J Rheumatol Suppl2006; 77: 3–11.
22.
MokMY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis2010; 13: 3–11.
23.
Ramos-CasalsMBrito-ZerónPMuñozSSotoMJ. BIOGEAS Study Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore)2008; 87: 345–364.
24.
GürcanHMKeskinDBSternJNNitzbergMAShekhaniHAhmedAR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol2009; 9: 10–25.
25.
FavasCIsenbergDA. B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?Nat Rev Rheumatol2009; 5: 711–716.
26.
García-CarrascoMJiménez-HernándezMEscárcegaRO. Use of rituximab in patients with systemic lupus erythematosus: An update. Autoimmun Rev2009; 8: 343–348.
27.
MerrillJTNeuweltCMWallaceDJ. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum2010; 62: 222–233.
28.
RovinBHFurieRLatinisK. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum2012; 64: 1215–1226.
29.
Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: A meta-analysis. Br J Haematol 2012: 386–398.
30.
TunNMVillaniGM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: A systematic review with pooled data analysis. J Thromb Thrombolysis2012; 34: 347–359.
31.
KumarDRoubeyRA. Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep2010; 12: 40–44.
32.
KneitzCWilhelmMTonyHP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology2002; 206: 519–527.
33.
HundaeAPeskoeSGrimsleyEPatelS. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J2008; 101: 943–944.
34.
TomiettoPGremeseETolussoBVenturiniPDe VitaSFerraccioliG. B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost2004; 92: 1150–1153.
35.
Van den BerghBSelleslagDBoelaertJR. Management of therapy-resistant systemic lupus erythematosus with rituximab: Report of a case and review of the literature. Acta Clin Belg2005; 60: 102–105.
36.
AhnERLanderGBidotCJJyWAhnYS. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol2005; 78: 127–129.
37.
ParanDTrej'oLCaspiD. Clinical images: B cell depletion in the appendix following rituximab treatment. Arthritis Rheum2006; 54: 2151–2151.
38.
AnandacoomarasamyAGibsonJMcGillN. ‘Cure’ of life-threatening antiphospholipid syndrome with rituximab. Intern Med J2006; 36: 474–475.
39.
NiewoldTBAlpertDScanzelloCRPagetSA. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol2006; 33: 1194–1196.
40.
NgKPCambridgeGLeandroMJEdwardsJCEhrensteinMIsenbergDA. B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response. Ann Rheum Dis2007; 66: 1259–1262.
41.
LimalNCacoubPSèneDGuichardIPietteJC. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus2008; 17: 69–71.
42.
FukushimaTDongLSakaiT. Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus2008; 17: 210–214.
43.
KittakaKDobashiHBabaN. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. Scand J Rheumatol2008; 37: 390–393.
44.
NadriQJ. Rituximab to treat active SLE in a hemodialysis patient. Saudi J Kidney Dis Transpl2009; 20: 1085–1086.
45.
ReisEAAthanazioDALimaI. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int2009; 29: 469–475.
46.
MardjuadiASoedirmanMUtoyoBRaskerJJ. Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: The first case report from Indonesia. Clin Rheumatol2009; 28(Suppl 1): S27–S30.
47.
LetchumananPNgHJLeeLHThumbooJ. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford)2009; 48: 399–403.
48.
LateefALahiriMTengGGVasooS. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus2010; 19: 765–770.
49.
ZhengWJZhangXWangQXuDZengXFZhangFC. Refractory severe connective tissue disease thrombocytopenia: Is rituximab treatment effective and safe?Ann Rheum Dis2009; 68: 1077–1078.
50.
LeeSYHsuPYJuanKCChangHHuangWHLaiPC. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus. Int Immunopharmacol2010; 10: 632–634.
51.
TerrierBAmouraZRavaudP. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum2010; 62: 2458–2466.
52.
NiazFAAleemA. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl2010; 21: 109–112.
53.
García-CarrascoMMendoza-PintoCSandoval-CruzM. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: A longitudinal analysis of 52 Hispanic patients. Lupus2010; 19: 213–219.
54.
GuptaRKEzeonyejiANThomasASScullyMAEhrensteinMRIsenbergDA. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Response to rituximab and cyclophosphamide. Lupus2011; 20: 1547–1550.
55.
PintoLFVelásquezCJPrietoCMestraLForeroEMárquezJD. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus2011; 20: 1219–1226.
56.
TewGWRabbeeNWolslegelK. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus2010; 19: 146–157.
57.
ErreGLPardiniSFaeddaRPassiuG. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: A case report and a review of literature. Lupus2008; 17: 50–55.
